Molina Healthcare, Inc. (NYSE: MOH) today announced details for the release of its results for the fourth quarter and year ended December 31, 2022.
Molina Healthcare will issue its earnings release for the fourth quarter and year ended December 31, 2022, after the market closes on Wednesday, February 8, 2023, and will host a conference call and webcast to discuss the earnings release on Thursday, February 9, 2023, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 3561497. A telephonic replay of the conference call will be available through Thursday, February 16, 2023, by dialing (877) 344-7529 and entering the confirmation number, 8594444.
A live broadcast of Molina Healthcare’s conference call will be available on the Company’s website, molinahealthcare.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company (currently ranked 125), provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. Molina Healthcare served approximately 5.2 million members as of September 30, 2022. For more information about Molina Healthcare, please visit molinahealthcare.com.
| Last Trade: | US$240.97 |
| Daily Change: | 1.97 0.82 |
| Daily Volume: | 632,303 |
| Market Cap: | US$13.780B |
November 18, 2024 October 23, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
